Obesity & OverweightNCT07341711
Long-term Adaptations of Skeletal Muscle After Hybrid Training
A study testing Exercise training in people with Obesity & Overweight, run by University of Thessaly at 1 site in Greece.
Trial summary
Obesity is a major challenge for public health and renders it imperative to reduce its prevalence. High intensity interval training (HIIT) is a form of exercise training that can efficiently induce weight loss in adults with overweight or obesity, even in the absence of dietary intake manipulation. Read more about this study
- Who is it for?
- Ages 30 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Obesity & Overweight
- What is being tested?
- Exercise training
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteGreece
- Study dates
- 8 Jan 2026to 20 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- BMI: >25 kg/m2 and <40 kg/m2
- Untrained individuals (abstain >1 year from exercise training)
- No dietary intervention over the last 6 months preceding the study
- Low cardiorespiratory fitness level (VO2max: <45 ml/kg/min)
- No use of any medication, dietary supplements
- Low risk for cardiovascular disease
- A weight loss <10% over the last 6 months preceding the study
- Free of non-communicable diseases (excluding metabolic syndrome)
Who cannot join
- Low participation rate (<80% completion of the exercise training sessions)
- Unbalanced diet
- Participation in additional exercise training regimes
- Cosumption of anti-inflammatory of pain relief medication
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Greece1 site, 1 recruiting
- Recruiting
Department of Physical Education and Sport Science Trikala, University of Thessaly
Trikala, Thessaly, 42100
Ioannis G Fatouros, Professor, +30 2431047047, ifatouros@uth.gr
Athanasios Z Jamurtas, Professor, +30 2431047054, ajamurt@uth.gr
About this study
Official title: Long-term Adaptations of Skeletal Muscle in Overweight and Obese Individuals After Hybrid Training
Obesity is a major challenge for public health and renders it imperative to reduce its prevalence. High intensity interval training (HIIT) is a form of exercise training that can efficiently induce weight loss in adults with overweight or obesity, even in the absence of dietary intake manipulation. Hybrid type training represents a form of HIIT, that incorporates both cardiorespiratory and musculoskeletal stimuli, by combining multiple types of exercise into a circuit-type, interval style workout. Recent evidence suggests that long-term participation in hybrid HIIT results in significant health-related benefits. However, the molecular mechanisms driving the chronic effects of hybrid HIIT on cardiometabolic and musculoskeletal health remains to be elucidated.
Read the detailed description
A total number of 30 adults (both males and females) aged 30-50, meeting the inclusion criteria, will be enrolled in this study. Participants will be randomly assigned to either (i) a Control group or (ii) an Intervention group. The Intervention group will participate in three hybrid-type HIIT sessions per week over a 6-month period while receiving a balanced diet. The Control group will receive a balanced diet over the 6-month period but will not participate in exercise training. At baseline and 6 months, both groups will undergo assessment of their anthropometric profile, body composition, resting metabolic rate, muscle strength and cardiorespiratory capacity and provide resting blood and skeletal muscle samples.
- Conditions
- Obesity & Overweight
- Being tested
- Exercise training, Control group
- Keywords
- obesity, overweight, high-intensity interval training, skeletal muscle
- Medical subject headings
- Obesity, Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Exercise trainingOther
Participants will perform a six-month hybrid training program while receiving a balanced diet. The periodization of hybrid training intervention will consist of three 2-month phases of gradually increased exercise intensity and volume. In every training will participate 5-8 individuals. The training will contain 6-12 different exercises (stations), depending on the phase of the intervention, which will be executed in a circuit for a total of 2-3 rounds, with 2-3 minutes of rest period between sets (depending on the phase). The exercise execution will last 20-45 seconds, and the rest between them will last 30-60 seconds (depending on the phase), while the exercise intensity will range from 75 to 85% of maximal heart rate. The stations of hybrid training will contain multi-joint exercises or neuromuscular activation exercises using either body weight resistance or portable equipment.
Control groupOther
Participants will receive a balanced diet but will not participate in any type of exercise training over a six month period.
| Study group | Role | What they receive |
|---|---|---|
| Intervention group | Experimental | Participants in this arm will participate in three hybrid-type HIIT sessions per week over a 6-month period while receiving a balanced diet Receives: Other: Exercise training |
| Control group | Active comparator | Participants in this arm will receive a balanced diet over the 6-month period but will not participate in exercise training Receives: Other: Control group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in mitochondrial size
Mitochondrial size will be measured using transmission electron microscope
Measured: At baseline and at 6 months
Change in mitochondrial density
Mitochondrial density will be measured using transmission electron microscope
Measured: At baseline and at 6 months
Change in mitochondrial count
Mitochondrial count will be determined using transmission electron microscope
Measured: At baseline and at 6 months
Change in mitochondrial distribution
Mitochondrial distribution will be determined using transmission electron microscope
Measured: At baseline and at 6 months
Change in maximum oxygen consumption (VO2max)
Maximum oxygen consumption (VO2max) will be assessed during a cardiopulmonary exercise testing by using a portable indirect calorimetry system
Measured: At baseline and at 6 months
Change in muscle fiber cross-sectional area
Muscle fiber cross-sectional area (μm2) will be measured using immunohistochemical staining for myosin heavy chain
Measured: At baseline and at 6 months
Change in PAX7+ satellite cells count
PAX7+ satellite cells will be determined using immunohistochemistry techniques.
Measured: At baseline and at 6 months
Change in total protein content
Total protein content (total RNA) will be determined in skeletal muscle tissue using real time quantitative-Polymerase Chain Reaction (q-PCR) technique
Measured: At baseline and at 6 months
Change in myonuclei content
Myonuclei content will be determined in skeletal muscle tissue using immunohistochemistry techniques
Measured: At baseline and at 6 months
Change in peroxisome proliferator-activated receptor-gamma coactivator -1a (PGC-1a) expression
PGC-1a expression in skeletal muscle tissue will be assessed using immunoblotting techniques.
Measured: At baseline and at 6 months
Change in Krebs cycle (TCA cycle) enzymes activity
Krebs cycle enzymes activity will be determined using the Seahorse XF Analyzer
Measured: At baseline and at 6 months
Change in protein expression of respiratory chain complexes
Protein expression of respiratory chain complexes will be determined using immunoblotting techniques
Measured: At baseline and at 6 months
Change in cytochrome C oxidase amount and expression
Cytochrome C oxidase amount and expression will be assessed using immunohistochemistry and immunoblotting techniques
Measured: At baseline and at 6 months
Change in ATP synthase amount and expression
ATP synthase amount and expression will be assessed using immunohistochemistry and immunoblotting techniques
Measured: At baseline and at 6 months
Change in citrate synthase amount and expression
Citrate synthase amount and expression will be assessed using immunohistochemistry and immunoblotting techniques
Measured: At baseline and at 6 months
Change in succinate dehydrogenase amount and expression
Succinate dehydrogenase amount and expression will be assessed using immunohistochemistry and immunoblotting techniques
Measured: At baseline and at 6 months
Change in NADH dehydrogenase amount and expression
NADH dehydrogenase amount and expression will be assessed using immunohistochemistry and immunoblotting techniques
Measured: At baseline and at 6 months
Change in mitochondrial oxygen consumption rate
Mitochondrial oxygen consumption rate will be determined using the Seahorse XF Analyzer
Measured: At baseline and at 6 months
Change in spare respiratory capacity
Spare respiratory capacity will be determined using the Seahorse XF Analyzer
Measured: At baseline and at 6 months
Change in mitochondrial maximal respiration
Maximal mitochondrial respiration will be determined using the Seahorse XF Analyzer
Measured: At baseline and at 6 months
Change in mitochondrial basal respiration
Mitochondrial basal respiration will be determined using the Seahorse XF Analyzer
Measured: At baseline and at 6 months
Change in non-mitochondrial respiration
Non-mitochondrial respiration will be determined using the Seahorse XF Analyzer
Measured: At baseline and at 6 months
Change in body fat percentage
Body fat percentage will be assessed using dual energy x-ray absorptiometry (DEXA)
Measured: At baseline and at 6 months
Change in diastolic arterial pressure
Diastolic blood pressure will be measured using a sphygmomanometer
Measured: At baseline and at 6 months
Secondary outcomes (30)
Change in density and distribution of capillaries
Capillarization will be determined using immunohistochemistry techniques
Measured: At baseline and at 6 months
Change in skeletal muscle fiber typing
Fiber typing will be determined using immunohistochemistry techniques
Measured: At baseline and at 6 months
Change in GLUT-4 protein expression
GLUT-4 protein expression will be assessed using immunoblotting techniques
Measured: At baseline and at 6 months
Change reduced glutathione content in skeletal muscle cells
Reduced glutathione content will be determined spectrophotometrically
Measured: At baseline and at 6 months
Change in glutathione peroxidase activity in skeletal muscle cells
Glutathione peroxidase activity will be determined spectrophotometrically
Measured: At baseline and at 6 months
Change in glutathione reductase activity in skeletal muscle cells
Glutathione reductase activity will be determined spectrophotometrically
Measured: At baseline and at 6 months
Change in superoxide dismutase activity in skeletal muscle cells
Superoxide dismutase activity will be determined spectrophotometrically
Measured: At baseline and at 6 months
Change in fasting glucose levels
Fasting glucose levels will be measured on an automated clinical chemistry analyzer
Measured: At baseline and at 6 months
Change in fasting insulin levels
Fasting insulin levels will be measured on an automated clinical chemistry analyzer
Measured: At baseline and at 6 months
Change in glycosylated hemoglobin levels
Glycosylated hemoglobin levels will be measured on an automated clinical chemistry analyzer
Measured: At baseline and at 6 months
Change in high-density lipoprotein (HDL) levels
HDL will be measured on an automated clinical chemistry analyzer
Measured: At baseline and at 6 months
Change in low-density lipoprotein (LDL) levels
LDL will be measured on an automated clinical chemistry analyzer
Measured: At baseline and at 6 months
Change in total cholesterol levels
Total cholesterol will be measured on an automated clinical chemistry analyzer
Measured: At baseline and at 6 months
Change in triglyceride levels
Triglycerides will be measured on an automated clinical chemistry analyzer
Measured: At baseline and at 6 months
Change in general blood count
General blood count will be measured on a hematology analyzer
Measured: At baseline and at 6 months
Change in erythrocyte reduced glutathione (GSH) levels
Erythrocyte GSH levels will be determined spectrophotometrically
Measured: At baseline and at 6 months
Change in erythrocyte oxidized glutathione (GSSG) levels
Erythrocyte GSSG levels will be determined spectrophotometrically
Measured: At baseline and at 6 months
Change in myostatin expression
Myostatin expression will be assessed using immunoblotting techniques
Measured: At baseline and at 6 months
Change cortisol concentration
Blood cortisol concentration will be assessed using immunoassays (ELISA)
Measured: At baseline and at 6 months
Change in testosterone concentration
Blood testosterone concentration will be assessed using immunoassays (ELISA)
Measured: At baseline and at 6 months
Change in growth hormone concentration
Blood growth hormone concentration will be assessed using immunoassays (ELISA)
Measured: At baseline and at 6 months
Change in insulin-like growth factor-1 (IGF-1) concentration
Blood IGF-1 concentration will be assessed using immunoassays (ELISA)
Measured: At baseline and at 6 months
Change in body mass
Body mass will be measured on a beam scale
Measured: At baseline and at 6 months
Change in bone density
Bone density will be assessed using dual energy x-ray absorptiometry (DEXA)
Measured: At baseline and at 6 months
Change in fat-free mass
Fat-free mass will be assessed using dual energy x-ray absorptiometry (DEXA)
Measured: At baseline and at 6 months
Change in waist circumference
Waist circumference will be measured using a Gullick II tape
Measured: At baseline and at 6 months
Change in hip circumference
Hip circumference will be measured using a Gullick II tape
Measured: At baseline and at 6 months
Change in resting heart rate
Heart rate will be measured using a heart rate monitor
Measured: At baseline and at 6 months
Change in resting metabolic rate (RMR)
RMR will be measured using indirect calorimetry
Measured: At baseline and at 6 months
Change in systolic arterial pressure
Systolic blood pressure will be measured using a sphygmomanometer
Measured: At baseline and at 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jan 2026
- Study start8 Jan 2026
- Primary completion30 Jun 2026 (estimated)
- Study completion20 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obesity & OverweightStudies of the same condition, open and under way.
- More trials run by University of ThessalyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Thessaly
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ioannis G. Fatouros, University of Thessaly
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07341711
- Sponsor's protocol ID
- 2482/4.12.2024
- Status last verified
- Oct 2025
- First submitted
- 5 Jan 2026
- Last updated
- 12 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long-term Adaptations of Skeletal Muscle in Overweight and Obese Individuals After Hybrid Training
- ClinicalTrials.gov ID
- NCT07341711
- Acronym / sponsor ID
- 2482/4.12.2024
- Conditions
- Obesity & Overweight
- Keywords
- obesity, overweight, high-intensity interval training, skeletal muscle
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- University of ThessalyUniversity, hospital or other
- Study start
- 8 Jan 2026 (actual)
- Primary completion
- 30 Jun 2026 (estimated)
- Study completion
- 20 Dec 2026 (estimated)
- First posted
- 14 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Obesity is a major challenge for public health and renders it imperative to reduce its prevalence. High intensity interval training (HIIT) is a form of exercise training that can efficiently induce weight loss in adults with overweight or obesity, even in the absence of dietary intake manipulation. Hybrid type training represents a form of HIIT, that incorporates both cardiorespiratory and musculoskeletal stimuli, by combining multiple types of exercise into a circuit-type, interval style workout. Recent evidence suggests that long-term participation in hybrid HIIT results in significant health-related benefits. However, the molecular mechanisms driving the chronic effects of hybrid HIIT on cardiometabolic and musculoskeletal health remains to be elucidated.
Detailed description
A total number of 30 adults (both males and females) aged 30-50, meeting the inclusion criteria, will be enrolled in this study. Participants will be randomly assigned to either (i) a Control group or (ii) an Intervention group. The Intervention group will participate in three hybrid-type HIIT sessions per week over a 6-month period while receiving a balanced diet. The Control group will receive a balanced diet over the 6-month period but will not participate in exercise training. At baseline and 6 months, both groups will undergo assessment of their anthropometric profile, body composition, resting metabolic rate, muscle strength and cardiorespiratory capacity and provide resting blood and skeletal muscle samples.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention group | Experimental | Other: Exercise trainingParticipants in this arm will participate in three hybrid-type HIIT sessions per week over a 6-month period while receiving a balanced diet |
| Control group | Active comparator | Other: Control groupParticipants in this arm will receive a balanced diet over the 6-month period but will not participate in exercise training |
Who may qualify
- Ages
- 30 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- BMI: >25 kg/m2 and <40 kg/m2
- Untrained individuals (abstain >1 year from exercise training)
- No dietary intervention over the last 6 months preceding the study
- Low cardiorespiratory fitness level (VO2max: <45 ml/kg/min)
- No use of any medication, dietary supplements
Key exclusion criteria (4 listed)
- Low participation rate (<80% completion of the exercise training sessions)
- Unbalanced diet
- Participation in additional exercise training regimes
- Cosumption of anti-inflammatory of pain relief medication
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Exercise trainingParticipants will perform a six-month hybrid training program while receiving a balanced diet. The periodization of hybrid training intervention will consist of three 2-month phases of gradually increased exercise intensity and volume. In every training will participate 5-8 individuals. The training will contain 6-12 different exercises (stations), depending on the phase of the intervention, which will be executed in a circuit for a total of 2-3 rounds, with 2-3 minutes of rest period between sets (depending on the phase). The exercise execution will last 20-45 seconds, and the rest between them will last 30-60 seconds (depending on the phase), while the exercise intensity will range from 75 to 85% of maximal heart rate. The stations of hybrid training will contain multi-joint exercises or neuromuscular activation exercises using either body weight resistance or portable equipment. | Other | Intervention group |
| Control groupParticipants will receive a balanced diet but will not participate in any type of exercise training over a six month period. | Other | Control group |
Primary outcome
Change in mitochondrial size
Time frame: At baseline and at 6 months
Mitochondrial size will be measured using transmission electron microscope
Change in mitochondrial density
Time frame: At baseline and at 6 months
Mitochondrial density will be measured using transmission electron microscope
Change in mitochondrial count
Time frame: At baseline and at 6 months
Mitochondrial count will be determined using transmission electron microscope
Change in mitochondrial distribution
Time frame: At baseline and at 6 months
Mitochondrial distribution will be determined using transmission electron microscope
Change in maximum oxygen consumption (VO2max)
Time frame: At baseline and at 6 months
Maximum oxygen consumption (VO2max) will be assessed during a cardiopulmonary exercise testing by using a portable indirect calorimetry system
Change in muscle fiber cross-sectional area
Time frame: At baseline and at 6 months
Muscle fiber cross-sectional area (μm2) will be measured using immunohistochemical staining for myosin heavy chain
Change in PAX7+ satellite cells count
Time frame: At baseline and at 6 months
PAX7+ satellite cells will be determined using immunohistochemistry techniques.
Change in total protein content
Time frame: At baseline and at 6 months
Total protein content (total RNA) will be determined in skeletal muscle tissue using real time quantitative-Polymerase Chain Reaction (q-PCR) technique
Change in myonuclei content
Time frame: At baseline and at 6 months
Myonuclei content will be determined in skeletal muscle tissue using immunohistochemistry techniques
Change in peroxisome proliferator-activated receptor-gamma coactivator -1a (PGC-1a) expression
Time frame: At baseline and at 6 months
PGC-1a expression in skeletal muscle tissue will be assessed using immunoblotting techniques.
Change in Krebs cycle (TCA cycle) enzymes activity
Time frame: At baseline and at 6 months
Krebs cycle enzymes activity will be determined using the Seahorse XF Analyzer
Change in protein expression of respiratory chain complexes
Time frame: At baseline and at 6 months
Protein expression of respiratory chain complexes will be determined using immunoblotting techniques
Change in cytochrome C oxidase amount and expression
Time frame: At baseline and at 6 months
Cytochrome C oxidase amount and expression will be assessed using immunohistochemistry and immunoblotting techniques
Change in ATP synthase amount and expression
Time frame: At baseline and at 6 months
ATP synthase amount and expression will be assessed using immunohistochemistry and immunoblotting techniques
Change in citrate synthase amount and expression
Time frame: At baseline and at 6 months
Citrate synthase amount and expression will be assessed using immunohistochemistry and immunoblotting techniques
Change in succinate dehydrogenase amount and expression
Time frame: At baseline and at 6 months
Succinate dehydrogenase amount and expression will be assessed using immunohistochemistry and immunoblotting techniques
Change in NADH dehydrogenase amount and expression
Time frame: At baseline and at 6 months
NADH dehydrogenase amount and expression will be assessed using immunohistochemistry and immunoblotting techniques
Change in mitochondrial oxygen consumption rate
Time frame: At baseline and at 6 months
Mitochondrial oxygen consumption rate will be determined using the Seahorse XF Analyzer
Change in spare respiratory capacity
Time frame: At baseline and at 6 months
Spare respiratory capacity will be determined using the Seahorse XF Analyzer
Change in mitochondrial maximal respiration
Time frame: At baseline and at 6 months
Maximal mitochondrial respiration will be determined using the Seahorse XF Analyzer
Change in mitochondrial basal respiration
Time frame: At baseline and at 6 months
Mitochondrial basal respiration will be determined using the Seahorse XF Analyzer
Change in non-mitochondrial respiration
Time frame: At baseline and at 6 months
Non-mitochondrial respiration will be determined using the Seahorse XF Analyzer
Change in body fat percentage
Time frame: At baseline and at 6 months
Body fat percentage will be assessed using dual energy x-ray absorptiometry (DEXA)
Change in diastolic arterial pressure
Time frame: At baseline and at 6 months
Diastolic blood pressure will be measured using a sphygmomanometer
30 secondary outcomes
Change in density and distribution of capillaries
Time frame: At baseline and at 6 months
Change in skeletal muscle fiber typing
Time frame: At baseline and at 6 months
Change in GLUT-4 protein expression
Time frame: At baseline and at 6 months
Change reduced glutathione content in skeletal muscle cells
Time frame: At baseline and at 6 months
Change in glutathione peroxidase activity in skeletal muscle cells
Time frame: At baseline and at 6 months
Change in glutathione reductase activity in skeletal muscle cells
Time frame: At baseline and at 6 months
Change in superoxide dismutase activity in skeletal muscle cells
Time frame: At baseline and at 6 months
Change in fasting glucose levels
Time frame: At baseline and at 6 months
Change in fasting insulin levels
Time frame: At baseline and at 6 months
Change in glycosylated hemoglobin levels
Time frame: At baseline and at 6 months
Change in high-density lipoprotein (HDL) levels
Time frame: At baseline and at 6 months
Change in low-density lipoprotein (LDL) levels
Time frame: At baseline and at 6 months
Change in total cholesterol levels
Time frame: At baseline and at 6 months
Change in triglyceride levels
Time frame: At baseline and at 6 months
Change in general blood count
Time frame: At baseline and at 6 months
Change in erythrocyte reduced glutathione (GSH) levels
Time frame: At baseline and at 6 months
Change in erythrocyte oxidized glutathione (GSSG) levels
Time frame: At baseline and at 6 months
Change in myostatin expression
Time frame: At baseline and at 6 months
Change cortisol concentration
Time frame: At baseline and at 6 months
Change in testosterone concentration
Time frame: At baseline and at 6 months
Change in growth hormone concentration
Time frame: At baseline and at 6 months
Change in insulin-like growth factor-1 (IGF-1) concentration
Time frame: At baseline and at 6 months
Change in body mass
Time frame: At baseline and at 6 months
Change in bone density
Time frame: At baseline and at 6 months
Change in fat-free mass
Time frame: At baseline and at 6 months
Change in waist circumference
Time frame: At baseline and at 6 months
Change in hip circumference
Time frame: At baseline and at 6 months
Change in resting heart rate
Time frame: At baseline and at 6 months
Change in resting metabolic rate (RMR)
Time frame: At baseline and at 6 months
Change in systolic arterial pressure
Time frame: At baseline and at 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Obesity & Overweight
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Exercise training in people with Obesity & Overweight, run by University of Thessaly at 1 site in Greece.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ioannis G Fatouros, Professor (24310 47047 ext. 0030, ifatouros@pe.uth.gr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in mitochondrial size (time frame: At baseline and at 6 months). The study lists 24 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2026.